BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase II
Galena Biopharma  (GALE) To Present GALE-401 (Anagrelide Controlled Release) Phase II Clinical Trial Data At The European Hematology Association 20th Congress 5/22/2015
Complete Data From RegeneRx Biopharmaceuticals, Inc. (RGRX) Phase II Dry Eye Trial Published In Current Issue Of Clinical Ophthalmology 5/22/2015
Otonomy (OTIC) Plunges After Near-Miss Stage IIb Trial for Ear Drug 5/22/2015
Otonomy (OTIC) Reports Phase IIb Topline Data for OTO-104 in Meniere's Disease 5/22/2015
OrthoTrophix Completed Subject Enrollment Of The Phase 2 Clinical Trial Of A New Cartilage Repair Therapeutic For Knee Osteoarthritis 5/21/2015
Johnson & Johnson (JNJ) Announced 10 New Approval Applications with $1 Billion Revenue Potential Each 5/21/2015
Lpath (LPTN) Shares Fall 80%, Will Cut Jobs After Second Drug Flunks Phase II Trial 5/21/2015
ICC Cohort Of Delcath Systems (DCTH)'s Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment 5/21/2015
CytRx Corporation (CYTR) Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer) 5/21/2015
EMD Serono, Inc. Release: Rebif (interferon beta-1a) Data At CMSC Annual Meeting Highlights Clinical And MRI Predictors For Long Term Outcomes 5/21/2015
Vical Incorporated (VICL) Announces Completion Of Enrollment In Phase II Clinical Trial Of Investigational CMV Vaccine In Kidney Transplant Recipients 5/21/2015
Amarantus BioSciences, Inc. Enters Into CRO Agreement With Chiltern International Ltd. To Commence Phase IIb Clinical Development Of Eltoprazine In Parkinson's Disease Levodopa-Induced Dyskinesia 5/21/2015
Theravance Biopharma Presents Additional Positive Phase 2b Study Data On TD-4208 For Treatment Of COPD At American Thoracic Society 2015 International Conference 5/21/2015
Investors Rejoice as bluebird bio (BLUE) Plots Road to First-Ever U.S. Gene Therapy Approval 5/20/2015
Ardelyx Inc. (ARDX) Presents Positive Results From Its Phase 2b Clinical Trial Evaluating Tenapanor In IBS-C Patients At Digestive Disease Week 2015 5/20/2015
Discovery Laboratories (DSCO) Announces Enrollment Of First Patient In AEROSURF Phase 2a Dose Expansion Trial 5/20/2015
TONIX Pharmaceuticals, Inc. (TNXP) To Present Additional Data From Completed Phase IIb Study Of TNX-102 SL In Fibromyalgia At EULAR 5/20/2015
Cesca Therapeutics Receives IEC/IRB Approval To Initiate Acute Myocardial Infarction Study 5/20/2015
Precision Biologics Completes Patient Accrual To Its Ensituximab Phase II Colorectal Cancer Study 5/20/2015
Kamada Ltd. (KMDA) Reports Updated Data From European Phase II/III Clinical Study Of Inhaled Alpha-1 Antitrypsin To Treat AAT Deficiency 5/20/2015
Genocea Biosciences Announces Positive Top-Line Phase 2 Data For Genital Herpes Immunotherapy GEN-003 5/20/2015
Ischemix Announces That Safety Review Committee For CARIN Trial Recommends Phase 2a Study To Continue As Planned 5/20/2015
Amgen (AMGN)'s Migraine Drug Meets Goals in Phase II Study 5/19/2015
Shionogi, Inc. Release: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation 5/19/2015
Targovax Announces Presentation Of Data From The Ongoing Phase I/II Clinical Study Of The RAS-Specific Therapeutic Cancer Vaccine TG01 In Resected Pancreatic Cancer At ASCO 2015 In Chicago 5/19/2015
Prima Biomed (PRR.AX) Release: CVAC Shows Overall Survival Benefit In Second Remission Ovarian Cancer In Phase II Study 5/19/2015
Sangamo BioSciences (SGMO) Presents New Data From Proprietary ZFP Therapeutic Programs For Lysosomal Storge Disorders At Annual Meeting Of The American Society Of Gene And Cell Therapy 5/18/2015
Intra-Cellular Therapies, Inc. Announces Further Analyses Of The Phase II Clinical Trial Of ITI-007 In Schizophrenia At The 168th Annual Meeting Of The American Psychiatric Association 5/18/2015
Marinus Pharmaceuticals (MRNS) Presents Clinical Data Of Ganaxolone In Pediatric Epilepsies At Antiepileptic Drug And Device Trials XIII Conference 5/18/2015
Kura Oncology Release: First Patient Dosed In Phase II Study Of Tipifarnib In Advanced Cancers With HRAS Mutations 5/18/2015
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting 5/18/2015
Mesoblast (MSB.AX) Release: Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting 5/18/2015
AbGenomics Corporation Announces Initiation Of Phase-Ib/Iia Clinical Trial Of Neihulizumab (AbGn-168H) For The Treatment Of Steroid Refractory Acute GvHD (aGvHD) 5/18/2015
Immune Pharmaceuticals, Inc. Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready To Enroll Patients 5/18/2015
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results And Provides Corporate Update 5/18/2015
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Pivotal Phase 2b Dupilumab Data In Asthma Presented At The American Thoracic Society 2015 International Conference 5/18/2015
Corbus Receives FDA Clearance To Initiate Phase 2 Clinical Study of Resunab For The Treatment Of Cystic Fibrosis 5/18/2015
Theravance Biopharma Presents Positive Phase 2 Study Data On Velusetrag (TD-5108) For Treatment Of Gastroparesis In "Poster Of Distinction" At Digestive Disease Week (DDW) 2015 5/18/2015
Amgen (AMGN) Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine 5/15/2015
Receptos (RCPT) Announces Oral Plenary Presentation Of TOUCHSTONE Phase II Induction Data At Digestive Disease Week 2015 5/15/2015
TRACON Pharmaceuticals, Inc. (TCON)'s TRC105 Receives FDA Fast Track Designation 5/15/2015
Alder Biopharma Presents Positive Clinical Data For ALD403 At The 17th Congress Of The International Headache Society 5/15/2015
Immunomedics, Inc. (IMMU) Awarded Fast Track Designation By FDA For Sacituzumab Govitecan For Non-Small Cell Lung Cancer Therapy 5/15/2015
Discovery Laboratories (DSCO) Announces Results Of Phase 2a Clinical Trial Of AEROSURF 5/14/2015
Asterias Biotherapeutics Announces Availability Of Abstract With Phase 2 Clinical Data On Cancer Vaccine AST-VAC1 In Acute Myelogenous Leukemia (AML) 5/14/2015
D-Pharm Ltd. Receives Final Report For Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 5/14/2015
Adynxx Completes Patient Enrollment In Phase 2 Dose-Ranging Study Of AYX1 For Prevention Of Post-Surgical Pain 5/14/2015
Immodulon Therapeutics Release: New Data From IMAGE 1 Show Improved Survival In Metastatic Pancreatic Cancer In Patients Receiving IMM-101 5/14/2015
Astellas Pharma Inc. (ALPMY) Announces New Data In Advanced Prostate And Breast Cancers, Acute Myeloid Leukemia, And Lung And Renal Cancers To Be Presented At 2015 ASCO Annual Meeting 5/14/2015
Sangamo BioSciences (SGMO) Provides Clinical Update On SB-728-T Program and Developments In Other ZFP Therapeutic Programs at American Society of Gene and Cell Therapy Annual Meeting 5/14/2015
Generex Biotechnology Corporation (GNBT) Provides Data Update From AE37 Phase II Breast Cancer Trial One Year Post Completion Of Enrollment 5/14/2015
Genentech (RHHBY)’s Investigational Immunotherapy MPDL3280A Doubled The Likelihood Of Survival Compared With Chemotherapy In People With A Specific Type Of Lung Cancer 5/14/2015
Agenus (AGEN) Announces Oral Presentation At ASCO Highlighting Improved Survival With Prophage Immunotherapy In Brain Cancer Compared To Historical Controls 5/14/2015
Corcept Therapeutics Inc. (CORT)' Mifepristone Combined With Eribulin To Improve Antitumor Activity In Patients With Triple-Negative Breast Cancer 5/14/2015
Teva (TEVA) Presents Further Data From Phase IIb With TEV-48125 In Chronic Migraine At The International Headache Society Congress (IHC): Efficacy And Safety Results At All Doses And Endpoints Present Robust Case For Progression To Phase III 5/14/2015
Celldex (CLDX) To Present Data From The React Study At 2015 ASCO Annual Meeting 5/14/2015
Galectin Therapeutics Reports No Drug-Drug Interaction Between GR-MD-02 And Midazolam 5/14/2015
GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin 5/13/2015
Fibrocell Science, Inc. Receives Rare Pediatric Disease Designation From FDA For FCX-007 For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 5/13/2015
Therabron Therapeutics Secures New Orphan Designation For The Prevention Of Bronchopulmonary Dysplasia 5/13/2015
Discovery Laboratories (DSCO) To Announce Results From AEROSURF Phase 2a Clinical Trial 5/13/2015
AbbVie (ABBV), Genentech (RHHBY) Leukemia Drug Wins Breakthrough Status Tag 5/11/2015
FDA Lifts Clinical Hold on NeuroDerm (NDRM)'s Lead Parkinson's Candidates 5/11/2015
Transition Therapeutics Inc. (TTH.TO) In-Licenses Phase 2 Drug Candidate From Eli Lilly (LLY) 5/11/2015
RXi Pharmaceuticals (RXII) Presented Promising New Data With Self-Delivering RNAi Compounds Targeting Tyrosinase And Collagenase 5/11/2015
TissueGene, Inc. Presents Phase 2 Data For Its Novel Cell Therapy For The Treatment Of Osteoarthritis Of The Knee 5/11/2015
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase II Nash Program 5/11/2015
Amarantus BioSciences, Inc. Reports Preliminary Data From Blood-Based Version Of Msprecise Diagnostic For Multiple Sclerosis 5/11/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Cavendish Global Health Impact Forum 5/11/2015
Can-Fite BioPharma (CFBI)'s Phase II Liver Cancer Trial Approved In Europe 5/11/2015
Zafgen (ZFGN) Presents Positive Safety And Efficacy Data From Phase II Trial Of Beloranib In Severe Obesity And Proof Of Concept Trial In Prader-Willi Syndrome At ECO 2015 5/8/2015
FDA Grants Fast Track Designation To Sucampo (SCMP)'s Cobiprostone For Oral Mucositis 5/8/2015
Eleven Biotherapeutics (EBIO) Presents Clinical Data On EBI-005 For The Treatment Of Dry Eye Disease And Allergic Conjunctivitis At Association for Research in Vision & Ophthalmology 2015 Annual Meeting 5/8/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report That Long-Term Administration Of Thymosin B4 In A Diabetic Animal Model Prevents Progression Of Peripheral Neuropathy And Restores Sciatic Nerve Function 5/8/2015
AbbVie (ABBV) And Genentech (RHHBY) Release: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17p Deletion Genetic Mutation 5/7/2015
MSI Methylation Sciences, Inc. (MSI) Completes Recruitment Of Phase 2 Trial For Its Novel Treatment STRADA For Major Depressive Disorder (MDD) 5/7/2015
Phosphate Therapeutics Announces Positive Results In The PEACH Pivotal Study Of Its Novel Phosphate Binder (PT20) For The Treatment Of Hyperphosphataemia 5/7/2015
MediciNova, Inc. Announces Full Enrollment In Phase 2b Trial Of MN-166 (Ibudilast) In Progressive MS 5/7/2015
Otonomy, Inc. (OTIC) Completes Enrollment In Phase II Clinical Trial For Auripro In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes 5/7/2015
Ohr Pharma (OHRP) Presents Data From OHR-102 Phase II IMPACT Study In Wet-AMD At Association for Research in Vision & Ophthalmology Conference 5/7/2015
(MSI) Completes Recruitment Of Phase 2 Trial For Its Novel Treatment STRADA For Major Depressive Disorder (MDD) 5/7/2015
NeuroVive: Published Data Indicates Protective Effect Of Cyclosporine In Patients With Stroke 5/7/2015
Tiny Corbus Looks to Give Vertex (VRTX) Some Competition With Experimental Cystic Fibrosis Drug 5/6/2015
Ardelyx Inc. (ARDX) Reports Results From Phase 2a Clinical Trial Evaluating Tenapanor In Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus And Albuminuria 5/6/2015
AbbVie (ABBV) Release: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17p Deletion Genetic Mutation 5/6/2015
GW Pharma (GWPH) Initiates Phase 2 Clinical Study Of Cannabidivarin (CBDV) In Epilepsy 5/6/2015
Parion Sciences Announces Initiation Of Phase 2 Clinical Study Of P-1037 For The Treatment Of Cystic Fibrosis 5/6/2015
Alexion (ALXN) Release: Researchers Present New Data From Phase 2 Clinical Trial Of Eculizumab (Soliris) In Prevention Of Acute Antibody-Mediated Rejection (AMR) In Sensitized Deceased-Donor Kidney Transplant Recipients 5/6/2015
Drug Trial Results For Remedy Pharmaceuticals, Inc.' CIRARA Could Change Stroke Treatment Forever, Saving And Improving Millions Of Lives 5/6/2015
Onxeo : Oral Presentation Of Phase II Trial Results Of Validive At The MASCC/ISOO International Symposium 5/6/2015
Alder Biopharma Announces Presentations At 17th Congress Of The International Headache Society On Data From ALD403 Clinical Trials 5/6/2015
Acacia Pharma Announces Positive Results From Phase 2 Study With APD403 In Chemotherapy Induced Nausea & Vomiting (CINV) 5/6/2015
Merrimack (MACK) Announces Initiation Of A Phase 2 Front-Line Clinical Trial Of MM-141 In Biomarker-Selected Patients With Metastatic Pancreatic Cancer 5/5/2015
Alder Biopharma Release: Clazakizumab, An Anti-IL-6 Monoclonal Antibody For The Treatment Of Rheumatoid Arthritis, Meets Primary Endpoint In Follow-On Phase IIb Clinical Trial 5/5/2015
Sorrento Therapeutics, Inc. Shows Off Positive TRIBECA Registrational Study Results 5/4/2015
Tocagen Inc. Presents Updated Interim Survival Data From Ongoing Clinical Studies At American Association Of Neurological Surgeons (AANS)/Congress Of Neurological Surgeons (CNS) Section On Tumors 5/4/2015
BioLineRx Ltd. Initiates Expansion Stage Of Phase 2 Clinical Trial For Novel Treatment For Acute Myeloid Leukemia 5/4/2015
Aquinox Pharmaceuticals (AQXP) Completes Enrollment In The Phase II KINSHIP Trial Of AQX-1125 In Atopic Dermatitis 5/4/2015
Cortex Pharmaceuticals, Inc. (COR) Announces Publication Of Research Results On The Use Of Ampakines CX1739 And CX717 In The Treatment Of Respiratory Disorders 5/4/2015
Allegro Ophthalmics LLC Begins Phase II Clinical Study Of Luminate® For Non-Proliferative Diabetic Retinopathy 5/4/2015
Generon (Shanghai) Corporation Ltd. Received FDA Clearance To Initiate Phase IIa Study With F-652, A First-In-Class Biologic, To Treat Patients With Acute GvHD 5/4/2015
Kadmon Corporation Initiates Second Phase 2 Clinical Trial Evaluating KD026 In Type 2 Diabetes 5/4/2015
Can-Fite BioPharma (CFBI) Subsidiary, OphthaliX, Signs Term Sheet To Acquire Improved Vision Systems Ltd. 5/4/2015
Auris Medical Holding AG Provides Update On Clinical Development Plan For AM-111 5/4/2015
Shanghai Generon To Start US Trial Of GvHD Biologic Drug 5/4/2015
OncoMed Pharmaceuticals, Inc. (OMED) Publishes Data On Tarextumab's Anti-Cancer Stem Cell Activity In Clinical Cancer Research 5/1/2015
Advanced Inhalation Therapies Granted European Orphan Drug Designation For Nitric Oxide For The Treatment Of Cystic Fibrosis 5/1/2015
TaiGen Biotechnology Starts China Trial Of Novel Chemotherapy Sensitizer 5/1/2015
TaiGen Biotechnology Announces Initiation of Burixafor Chemosensitization Clinical Trial In Acute Myeloid Leukemia In China 4/30/2015
OncoMed Pharmaceuticals, Inc. (OMED) Highlights Immuno-Oncology Discoveries During 2015 Research & Development Day 4/30/2015
Ocata Therapeutics Announces Positive Results In Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells In Asian Patients 4/30/2015
Eleven Biotherapeutics (EBIO) Publishes Clinical Data On EBI-005 For The Treatment Of Allergic Conjunctivitis 4/29/2015
CytRx Corporation (CYTR) Announces Publication Of Glioblastoma Clinical Case Study In Journal Of Nuclear Medicine & Radiation Therapy 4/29/2015
Amarantus BioSciences, Inc. Granted European Union Orphan Drug Designation For MANF For The Treatment Of Retinitis Pigmentosa 4/29/2015
Tyrogenex, Inc. Initiates The APEX Study, A Phase II Trial Of Oral Treatment With X-82 For Wet AMD 4/29/2015
Advancing Biogen (BIIB)’s Alzheimer’s Treatment Could Cost $2.5 Billion Before Knowing if the Drug Works 4/28/2015
Celladon (CLDN) Will Lay Off Workers, Loses 80% of Value As Heart Failure Drug Flunks Phase IIb Trial 4/28/2015
Cerulean Pharma Inc. (CERU) Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma 4/28/2015
PRANA Biotechnology (PRAN) Release: PBT2 Recommended For Orphan Designation In Europe 4/28/2015
Bio-Path Holdings, Inc. (BPTH) Granted Orphan Drug Designation For Liposomal Grb-2 In Acute Myeloid Leukemia 4/28/2015
FDA Grants Fast Track Designation To Genzyme (GENZ)’s Investigational Substrate Reduction Therapy For The Treatment Of Fabry Disease 4/28/2015
Merck & Co. (MRK) Poised To Enter Oral HCV Market Dominated by Gilead (GILD) and AbbVie (ABBV) 4/27/2015
aTyr Pharma Receives U.S. FDA Orphan Designation For Resolaris 4/27/2015
VentiRx Pharmaceuticals, Inc. Granted Orphan Drug Designation In The European Union For Motolimod In The Treatment Of Ovarian Cancer 4/27/2015
Celsion Corporation (CLSN) Announces Appointment Of Harriet Shelare To Director, Communications 4/27/2015
Achillion (ACHN) Presents Detailed Clinical Results On ACH-3102 And ACH-3422 At The International Liver Congress 4/27/2015
Eiger Biopharma Announces Interim Results Of Lonafarnib In Combination With Ritonavir Or Pegylated Interferon In Patients Infected With Hepatitis Delta Virus (HDV) 4/27/2015
Imperial Innovations Release: Autifony Therapeutics Recruits First Patient Into Phase IIa Trial For Age Related Hearing Loss 4/27/2015
NeuroVive: FIrst Patient Enrolled In Clinical Phase II Study For Kidney Protection During Heart Surgery 4/27/2015
Gilead (GILD) Announces Results From Studies Evaluating Sofosbuvir-Based Regimens In Chronic Hepatitis C Patients With Genotypes 2-5 4/27/2015
Celladon (CLDN) Reports Negative Results For CUPID2 Trial Of MYDICAR In Advanced Heart Failure 4/27/2015
Amgen (AMGN) Boasts 51% Rise in Profit, Abandons Phase II Brodalumb Study, but Pushes Biosimilars 4/24/2015
Baseline Characteristics Of 228 Subjects Enrolled In MediciNova, Inc.'s Phase IIb Trial Of MN-166 (Ibudilast) In Progressive MS Presented At The American Academy of Neurology 67th Annual Meeting 4/24/2015
FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna (DRNA)’s Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1) 4/24/2015
Merck & Co. (MRK) Announces Results From Phase 2/3 Study Of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir In Patients With Advanced Chronic Kidney Disease 4/23/2015
Gilead (GILD)’s Harvoni And Sovaldi Demonstrate Efficacy And Safety Among Chronic Hepatitis C Patients With Advanced Liver Disease 4/23/2015
Merck & Co. (MRK) Touts Results From C-SURFER Phase II/III Clinical Trial 4/23/2015
Ultragenyx Pharmaceuticals (RARE) Granted Additional Orphan Drug Designations For Triheptanoin 4/23/2015
Debiopharm Initiates Clinical Phase II Study Evaluating Debio 1450 In Staphylococcal Skin Infections 4/23/2015
Conatus Pharma Clinical Results At EASL Meeting Support Emricasan Registration Pathway In NASH 4/23/2015
Intercept Ltd. Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution And Cirrhosis Prevention In High-Risk NASH Patients 4/23/2015
Mitotech Announces Phase 2 Data Showing Positive Effect Of SkQ1 In Patients With Dry Eye Syndrome 4/23/2015
Teva (TEVA) And Active Biotech AB (BTPC) Announce First Patient Enrolled In Phase II Study Evaluating Laquinimod For Primary Progressive MS 4/23/2015
Roche (RHHBY) Still Bullish on Alzheimer’s Research After Biogen (BIIB)’s Successful Clinical Trial 4/22/2015
FDA, Genervon and ALS Blogger Battle Over Clinical Trial Interpretation 4/22/2015
Ultragenyx Pharmaceuticals (RARE) Announces Positive Data From Investigator-Sponsored Trial Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome 4/22/2015
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Dosing In Randomized Phase 2 Clinical Trial Of Demcizumab In Pancreatic Cancer Patients 4/22/2015
Genocea Biosciences Completes Enrollment In Phase IIa Human Challenge Study Of GEN-004 For The Prevention Of Infection By Pneumococcus 4/22/2015
Biothera’s Investigational Cancer Immunotherapy Alleviates Immune Suppression By Regulatory T Cells, Enabling CD4 And CD8 T Cell Proliferation, Study Finds 4/22/2015
GlobeImmune, Inc. (GBIM) Announces Opening Of Randomized Phase 2 Chordoma Trial At National Cancer Institute 4/22/2015
Nuvo Research Inc. (NRI.TO) Announces New WF10 Phase 2 Trial 4/22/2015
Lightlake Therapeutics Inc. (LLTP) Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study 4/22/2015
Viralytics Ltd (VLA.AX) Update On CALM And STORM Clinical Trials At AACR Annual Meeting 4/22/2015
Pharmaleads Announces The Inclusion Of The First Patient In Phase IIa Study Of Oral PL37 For Pain In Diabetic Neuropathy 4/22/2015
SCRA Technology Ventures Company Shares Phase 2 Results 4/22/2015
Alnylam (ALNY)'s Phase II Study Confirms Effectiveness of RNAi Drugs 4/21/2015
BrainStorm Cell Therapeutics Inc. Says Stem Cell Drug Benefits ALS Patients in Mid-Stage Trial 4/21/2015
Alnylam (ALNY) Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational Rnai Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP) 4/21/2015
Argos Therapeutics, Inc. (ARGS) Announces Publication Of Data From Phase 2 Clinical Trial Of AGS-003 Fully Personalized Immunotherapy For Treatment Of Metastatic Renal Cell Carcinoma (mRCC) 4/21/2015
Genzyme (GENZ) Initiates Phase 2a Clinical Trial To Evaluate Oral Therapy For Fabry Disease 4/21/2015
NeuroVive: Clinical Phase II Study With Neurostat For Traumatic Brain Injury Passes Safety Evaluation 4/21/2015
Biothera’s Imprime PGG Cancer Immunotherapy Drug Candidate Shows Potential To Enhance Efficacy Of Immune Checkpoint Inhibitors 4/21/2015
Biothera’s Imprime PGG Investigational Immunotherapy Drug Modulates The Function Of Macrophages And Dendritic Cells To Drive Expansion Of Anti-Cancer T Cells 4/21/2015
New Data Demonstrate Potential Of Biothera’s Investigational Cancer Immunotherapy To Re-Orient The Tumor Microenvironment To Facilitate Greater Anti-Tumor Activity 4/21/2015
Biothera’s Investigational Cancer Immunotherapy Drug Imprime PGG Elicits Dramatic Expansion Of Cytotoxic T Cells 4/21/2015
FDA Grants Fast Track Designation To Eiger Biopharma's Lonafarnib For Hepatitis Delta Virus (HDV) Infection 4/20/2015
Patients With Advanced Breast, Lung, Esophageal, And Colorectal Cancers Respond To Immunomedics, Inc. (IMMU)' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments 4/20/2015
Genticel To Present Further Promising Pharmacology In-Vivo Results Of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (Procervix), At AACR Annual Meeting 2015 4/20/2015
Anika Therapeutics (ANIK)' Cingal 13-02 Study Meets Primary Endpoint 4/20/2015
Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals, Inc.'s NP001 Potential Efficacy And Safety In ALS 4/20/2015
Pluristem Therapeutics (PSTI)'s Clinical Advisory Board Prepares Phase II Clinical Trials In Critical Limb Ischemia In Europe And Japan 4/20/2015
Atara Biotherapeutics (ATRA)' Collaborating Investigators' Abstract On T-Cell Therapy For EBV Lymphoma To Be Presented At A Clinical Trials Plenary Session At The American Association for Cancer Research Annual Meeting 2015 Is Now Available 4/20/2015
Otonomy, Inc. (OTIC) Completes Enrollment Of OTO-104 Multiple-Dose Safety Study In Meniere's Disease Patients 4/20/2015
EBV-CTL Clinical Trial Data Presented By Atara Biotherapeutics' Collaborating Investigators At A Plenary Session At The AACR Annual Meeting 2015 4/20/2015
Bionomics Limited (BNO.AX) Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 4/20/2015
Nymox Pharmaceutical (NYMX) Announces New Prostate Cancer Clinical Trial Results 4/20/2015
DelMar Pharmaceuticals Presents Updated Clinical Data On Phase I/II Study Of VAL-083 In Refractory Glioblastoma Multiforme (GBM) 4/20/2015
Immunocore Limited Announces Positive Clinical Trial Data For Novel First-in-Class Immunotherapy At AACR Annual Meeting 2015 4/20/2015
Can-Fite BioPharma (CFBI) Applies For Orphan Drug Designation In Europe For CF102 In The Treatment Of Liver Cancer 4/20/2015
Opexa Therapeutics (OPXA) Invited To Present Biomarker Data From NMO Patients At The American Academy of Neurology 2015 Annual Meeting 4/20/2015
Halozyme Therapeutics, Inc. (HALO) Presents New Preclinical Data At AACR Annual Meeting, Announces Clinical Data Presentation At ASCO 4/20/2015
Kamada Ltd. (KMDA) Reports Additional Data From European Phase 2/3 Clinical Study Of Inhaled Alpha-1 Antitrypsin To Treat AAT Deficiency 4/20/2015
Pharmacyclics (PCYC) Release: IMBRUVICA (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, In Patients With Chronic Lymphocytic Leukemia (CLL) 4/20/2015
Bristol-Myers Squibb (BMY) Release: First Randomized Study Evaluating Opdivo (Nivolumab)+Yervoy (Ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone In Patients With Previously Untreated Advanced Melanoma 4/20/2015
Discovery Laboratories (DSCO) Ceasing Production of Lead Drug Surfaxin, Chops 50% Employees 4/17/2015
Athersys (ATHX) Craters as Stem Cell Therapy Fails Phase II Stroke Study 4/17/2015
Targacept (TRGT) Winces As Last Remaining Drug Candidate Flops in Phase II Trial 4/17/2015
RXi Pharmaceuticals (RXII) Receives Orphan Drug Designation For Samcyprone From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb to IV 4/17/2015
Bionomics Limited (BNO.AX) Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting 4/17/2015
Athersys (ATHX) Announces Results From Phase 2 Study Of Multistem Cell Therapy For Treatment Of Ischemic Stroke 4/17/2015
Anika Therapeutics (ANIK) Reports On Cingal 13-01 Study Clinical Trial Top Line Data And Announces The Completion Of Cingal 13-02 Study’s Patient Enrollment 4/17/2015
Burzynski Research Institute Announces Publication Of Phase II Results In Patients With Non-Diffuse Intrinsic Pontine Glioma 4/17/2015
Ariad (ARIA) Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer 4/17/2015
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015
Aldeyra Therapeutics (ALDX) Announces First Patient Enrolled In Noninfectious Anterior Uveitis Phase II Clinical Trial 4/16/2015
Receptos (RCPT) Reports Positive Results For The Maintenance Period Of The Phase 2 TOUCHSTONE Trial Of Ozanimod In Ulcerative Colitis 4/16/2015
StemCells (STEM) Completes Enrollment Of First Cohort In Phase II Pathway Study For Cervical Spinal Cord Injury 4/16/2015
EMD Serono Highlights Scientific Commitment To MS With Data Presented At The American Academy of Neurology Annual Meeting 4/16/2015
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-001 (Tipelukast) For The Treatment Of NASH With Fibrosis 4/16/2015
Celgene (CELG) Release: Phase II Data For Apremilast In Behçet’s Disease Published In The New England Journal of Medicine 4/16/2015